Jasper Therapeutics Financials - Benzinga

Jasper Therapeutics Inc

JSPRNASDAQ

Trade with Public

Trade with Public

$0.6070

-0.0184-2.94%

마지막 업데이트: Sep 29, 7:54 PM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Jasper Therapeutics Financials

Jasper Therapeutics (JSPR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Jasper Therapeutics Q2 EPS $(0.10) Beats $(0.26) Estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 94.25 percent increase over losses of $(1.74) per share

Benzinga Newsdesk

PRO
Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.64) by 50.31 percent. This is a 80.25 percent increase over losses of $(1.62) per share

Benzinga Newsdesk

PRO
Jasper Therapeutics Q3 EPS $(1.13) Beats $(1.28) Estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.28) by 12.06 percent. This is a 8.87 percent increase over losses of $(1.24) per share

Benzinga Newsdesk

PRO
Jasper Therapeutics Q2 EPS $(1.74) Misses $(1.40) Estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of $(1.40) by 24.55 percent. This is a 79.38 percent decrease over losses of $(0.97) per share

Benzinga Newsdesk

Dow Dips 1%; Mustang Bio Shares Spike Higher

Avi Kapoor

PRO
Jasper Therapeutics Q1 EPS $(1.41) Misses $(1.33) Estimate

Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.41) per share which missed the analyst consensus estimate of $(1.33) by 6.02 percent. This is a 36.89 percent decrease over losses of $(1.03) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved